{"schema_version":"secwatch.filing_event.v1","accession":"0000937556-24-000106","form_type":"8-K","ticker":"MASI","cik":"0000937556","company_name":"MASIMO CORP","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.442098+00:00","generated_at":"2026-05-30T05:44:41.048806+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Masimo Q3 healthcare revenue up 11.7% CC; raises FY non-GAAP EPS guidance to $3.95-$4.10","bullets":["Healthcare revenue $343.3M (+11.7% CC); total revenue $504.6M; 60,500 board/instrument shipments.","GAAP EPS $0.18; Non-GAAP EPS $0.98; GAAP operating income $30.1M, non-GAAP $80.8M.","Raised FY2024 non-GAAP EPS guidance to $3.95-$4.10 from prior $3.80-$4.00; operating income $325-$336M.","Narrowed FY total revenue guidance to $2.075-$2.105B from $2.085-$2.135B; healthcare $1.390-$1.400B.","Interim CEO cites ongoing portfolio review, R&D focus on sizable markets, and strategic review of consumer business."],"urls":{"canonical":"https://secwatch.observer/filing/0000937556-24-000106","json":"https://secwatch.observer/filing/0000937556-24-000106.json","markdown":"https://secwatch.observer/filing/0000937556-24-000106.md","text":"https://secwatch.observer/filing/0000937556-24-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000106/0000937556-24-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000106/masi-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:44:41.048806+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}